SureTrader Stock Hero Advertisement SureTrader SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BigKahuna, BooDog, KarinCA, noretreat, TOB, starbuxsux
Search This Board:
Last Post: 5/25/2015 1:27:35 AM - Followers: 587 - Board type: Free - Posts Today: 5

Cellceutix Corporation (CTIX) 
 

 

http://cellceutix.com/
 

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com
 
CIK:  0001355250
 
Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in a bioequivalence crossover clinical trial in Miami, FL. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, is in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna.

 

Management:   http://cellceutix.com/team/
The above link is kept updated.
http://www.zoominfo.com/p/Daniel-Jorgensen/1064701588
 

 
Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/
 

 
Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx

 
SEC Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:
EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  info@cellceutix.com

Following is a WEEKLY chart:


 
 

 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
Wiki
CTIX News: *Special Analyst Alert* and 4 Companies that are Worth a Look 05/13/2015 07:00:00 AM
CTIX News: Quarterly Report (10-q) 05/11/2015 02:03:16 PM
CTIX News: Current Report Filing (8-k) 04/27/2015 07:34:19 AM
CTIX News: Securities Registration (section 12(b)) (8-a12b) 04/27/2015 06:28:28 AM
CTIX News: Cellceutix closes $30M stock purchase agreement 04/01/2015 08:59:20 AM
PostSubject
#103874  Sticky Note Special Alert from CEO BigKahuna 05/22/15 02:45:18 PM
#103486  Sticky Note CTIX May 21st “Understanding QIDP and Other 21st BooDog 05/21/15 11:36:36 AM
#95145  Sticky Note $CTIX Lead drug info, News, SEC filings, FDA KarinCA 03/21/15 12:39:45 PM
#92697  Sticky Note upcoming catalysts slcimmuno 02/26/15 09:18:08 AM
#87958  Sticky Note Cellceutix Reports Spleen Lesion 'Disappears' in Patient With starbuxsux 01/20/15 08:25:55 AM
#74575  Sticky Note Cellceutix Announces Positive Top-Line Data From Phase 2b TOB 10/23/14 11:59:10 AM
#104269   Kevetrin's safety will allow more options for dosing. farrell90 05/25/15 01:27:35 AM
#104268   The University of Bolonga Kevetrin trial for AML farrell90 05/25/15 01:02:29 AM
#104267   We do know that PK-PD modeling for Brilacidin biodoc 05/25/15 12:57:49 AM
#104266   Brilacidin has important qualities which allows once daily farrell90 05/25/15 12:32:13 AM
#104264   Can you believe that you can buy this scgmck1 05/24/15 11:23:03 PM
#104262   Funny, To infinity..., I was thinking about the biodoc 05/24/15 10:36:24 PM
#104261   Leo punched "them" right in the mouth when 25 Kilos of Gold 05/24/15 10:30:02 PM
#104260   Who are they? Do I need special glasses? TheDane 05/24/15 10:00:12 PM
#104259   Let em have it GOV! They should all Ultimate01 05/24/15 09:48:21 PM
#104258   Double E....FDA meeting with Cellceutix end of June............ who Matagordaville 05/24/15 09:41:59 PM
#104257   I'm on your side, Fletch 05/24/15 09:05:14 PM
#104254   How do they decide? Look, if you were To infinity and beyond! 05/24/15 08:50:27 PM
#104253   Just looked my favorites and saw 351 posts. incubus-now 05/24/15 08:42:54 PM
#104252   this is the first time since i have govorchin 05/24/15 08:34:49 PM
#104251   I can't wait to get my paws on TheHound 05/24/15 08:18:16 PM
#104250   Management is clearly confident. It's good they're planning frrol 05/24/15 08:08:59 PM
#104249   You're going to be disappointed asking a board frrol 05/24/15 07:55:39 PM
#104248   If he did he's clueless....................it's a ihub circus, LOL. etradeedge 05/24/15 07:42:25 PM
#104247   Planning a Phase 2/3 trial before the completion sox040713 05/24/15 06:12:13 PM
#104246   Monolith, good post! I agree with the causes sox040713 05/24/15 06:04:21 PM
#104245   I agree with you. But then again daydreaming2 05/24/15 03:27:09 PM
#104243   i am not sure but i think leo govorchin 05/24/15 03:23:34 PM
#104242   I'm with you. Enough of the posts tduggan 05/24/15 03:15:36 PM
#104241   How about we just wait and see where tombrady12nh 05/24/15 02:44:25 PM
#104240   Ok this is it. Line in the sand. Last post bramkers 05/24/15 02:40:10 PM
#104239   Maybe he's looking at short volume and doesn't TheHound 05/24/15 02:37:51 PM
#104238   In my opinion Leo isn't focused on shorting. scottsmith 05/24/15 02:31:44 PM
#104237   Good write up Amatuer17 05/24/15 02:26:04 PM
#104236   Best post of the day. bramkers 05/24/15 02:24:26 PM
#104235   Oops. Yes I meant stage 1. DaubersUP 05/24/15 02:07:47 PM
#104234   Nonsense DD2. TheHound 05/24/15 01:43:38 PM
#104233   Whether or not short interest is playing a TheHound 05/24/15 01:43:02 PM
#104232   I would never be in a stock without BIzzy 05/24/15 01:41:24 PM
#104231   Sox, It's not the email that was the TheMonolith 05/24/15 01:40:04 PM
#104230   Right. Drano 05/24/15 01:32:06 PM
#104229   Actually you are very incorrect the numbers you daydreaming2 05/24/15 01:22:00 PM
#104228   I have yet to read anything that says frrol 05/24/15 01:16:08 PM
#104227   I must of missed the naked short memo TheHound 05/24/15 01:08:53 PM
#104226   Short interest is a snapshot of the number Drano 05/24/15 01:00:53 PM
#104225   Agreed... But, it may have different formulations down KarinCA 05/24/15 12:40:53 PM
#104224   I doubt that any doctor would consider giving georgejjl 05/24/15 12:35:40 PM
#104223   then how do you explain a disappearing spleen lesion? Waverunner1 05/24/15 12:34:32 PM
#104222   Are you meaning to say "stage 1 cancer"? KarinCA 05/24/15 12:09:51 PM
#104220   Key DD. End of June meeting w DaubersUP 05/24/15 12:06:34 PM
#104219   They do seem to be actually getting to NewMoney 05/24/15 11:53:08 AM
#104218   When does Kevetrin get to go against phase DaubersUP 05/24/15 11:52:45 AM
#104217   T + 3 and it's official. Until then etradeedge 05/24/15 11:52:13 AM
#104216   Thanks Rosterman 05/24/15 11:42:33 AM
#104215   Rosterman: I doubt that the researcher even knows about georgejjl 05/24/15 11:41:03 AM
#104214   Do you know if this researcher used the Rosterman 05/24/15 11:34:20 AM
PostSubject